Related Experiment Video

Updated: May 22, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical

Libero Santarpia1, Yuan Qi, Katherine Stemke-Hale

  • 1Department of Oncology, Translational Research Unit, Hospital of Prato and Istituto Toscano Tumori, 59100, Prato, Italy. lsantarpia@usl4.toscana.it

Breast Cancer Research and Treatment
|April 28, 2012
PubMed

Insights

This study identified common gene mutations in different breast cancer subtypes, finding that 40% of tumors had targetable mutations. This supports using molecular profiling for personalized breast cancer treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer comprises distinct molecular subtypes with varying prognoses.
  • The mutation landscape across these subtypes is not fully characterized.
  • Understanding subtype-specific mutations is crucial for targeted therapy development.

Purpose of the Study:

  • To identify actionable mutations in key genes across major breast cancer subtypes: estrogen receptor-positive/HER2-negative, HER2-positive, and triple-negative breast cancer (TNBC).
  • To assess the feasibility of simultaneous mutation detection in fine needle aspirates for clinical trial design.

Main Methods:

  • DNA extraction from 267 fine needle aspirations of stage I-III breast cancers.
  • Sequenom technology used to analyze 28 genes for 163 known cancer-related mutations.
  • Validation of detected mutations using allele-specific PCR or direct sequencing.

Main Results:

  • Mutations were found in 40% of samples across 15 genes.
  • PIK3CA mutations were most common (16.1%), particularly in ER+ and HER2+ subtypes.
  • FBXW7 mutations were more frequent in TNBC compared to ER+ breast cancer.
  • PHLPP2 polymorphism, activating AKT, was observed in 13.5% of samples.

Conclusions:

  • Distinct breast cancer molecular subtypes exhibit unique mutation profiles.
  • Approximately 40% of breast cancers harbor targetable mutations in signaling pathways.
  • Multiplex mutation testing on fine needle aspirates is feasible for guiding future clinical trials.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...